PHER O2
Latest Information Update: 04 Nov 2017
At a glance
- Originator Sanguine Corporation
- Class Fluorocarbons
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Hypovolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypovolaemia in USA (IV)
- 06 Dec 2006 Sanguine has met with the US FDA to discuss the appropriate regulatory path for PHER 02